Proteomics and biomarkers for detection of ovarian cancer

Czech version

Authors: M. Kacerovský ¹; V. Tambor ²; J. Lenčo ²; J. Tošner ¹
Authors‘ workplace: Porodnická a gynekologická klinika FN Hradec Králové, Lékařská fakulta Hradec Králové, Univerzita Karlova Praha, přednosta doc. MUDr. J. Tošner, CSc. ¹; Ústav molekulární patologie, Fakulta vojenského zdravotnictví Univerzity Obrany Hradec Králové, přednosta prof. MUDr. J. Stulík, CSc. ²
Published in: Ceska Gynekol 2009; 74(3): 163-170

Overview

Objective:
The purpose of this study was to focuse on recent developments on the evolving field of biomarker discovery and validation techniques using proteomics platforms for ovarian cancer.

Design:
Review.

Setting:
Department of Obstetrics and Gynecology Medical Faculty Charles University Hradec Kralove. Institute of Molecular Pathology. Faculty of Military Health Sciences, University of Defense, Hradec Kralove.

Methods:
The last decade has seen major changes in the technologies used to identify markers for diagnosing early stages of ovarian cancer. Currently the major developments were made in three distinct areas: protein profilig, highthroughput validation techniques and solid and liquid phase protein microarray platforms for analyzing candidate markers across stages hold significant of ovarian cancer. These new technologies hold significant promise in identifying more robust markers for ovarian cancer.

Conclusion:
The present review summarizes the results of clinical and experimental research on biomarkers of ovarian cancer.

Key words:
proteomics, ovarian cancer, biomarker.

Sources

1. Aebersold, R. A mass spectrometric journey into protein and proteome research. J Am Soc Mass Spectrom, 2003, 14, p. 685-695.

2. Bast, RC Jr., Knauf, S., Epenetos, A., Dhokia, B. Coordinate elevation of serum markers in ovarians cancer but not in benign disease. Cancer, 1991, 68, p. 1758-1763.

3. Bast, RC Jr., Klug, TL., St John, E., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epitelial ovarian cancer. N Engl J Med, 1983, 309, p. 883-887.

4. Bast, RC Jr., Knapp, RC. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol, 1985, 19, p. 354-356.

5. Bast, RC Jr., Xu, FJ., Yu, YH., Barnhill, S., et al. CA -125: The past and the future. Int J Biol Markers, 1998, 13., p. 179-187.

6. Bastl, RC Jr., Badgwell, D., Lu, Z. CA-125 and beyond. Int J Gynecol Cancer, 2005, 15, p. 274-281.

7. Berek, JS, Bast, RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer, 1995, 76, p. 2092-2096.

8. Bornogo, CA., Kishi, T., Scorilas, A., Harbeck, N. Human kallikrein 8 protein is a favorable prognostic marker in ovarian cancer. Clin Cancer Res, 2006, 12, p. 1487-1493.

9. Bondarenko, PV., Chelius, D., Shaler, TA. Identification and relative quantification of protein mixtures by enzymatic digestion followed by capillary reversed – phase liquid chromatography – tandem mass spektrometry. Anal Chem, 2002, 15, p. 4741-4749.

10. Bristow, RE., Berek, JS. Surgery for ovarian cancer: How to improve survival. Lancet, 2006, 367, p. 1558-1560.

11. Conrads, TP., Fusaro, VA., Ross, S., et al. High-resolution serum proteomics features for ovarian cancer detection. Endocr Relat Cancer, 2004, 11, p. 163-178.

12. Daoud, E., Bodor, G. CA 125 concentration in malignit and nonmalignant disease. Clin Chem, 1991, 37, p. 1968-1974.

13. Dekker, LJ., Boogerd, W., Stockhammer, G., et al. MALDI-TOF mass spektrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patiens with breast cancer. Mol Cell Proteomics, 2005, 4, p. 1341-1349.

14. Denkert, C., Budzies, J., Kind, T., et al. Mass spektrometry – based metabolic profilig revers different metabolite patterns in invasive ovarian carcinomas and ovarian boderline tumors. Cancer Res, 2006, 66, p. 10795-10804.

15. Diamandis, EP., Scorilas, A., Fracchioli, S., Van Gramberen, M. Human kallikrein. A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol, 2003, 21, p. 1035-1043.

16. Feng, H., Ghazizadeh, M., Konishi, H., Araki, T. Expression of MUC1 and MUC2 mucin gene produc ts in human ovarian carcinomas. Jpn J Clin Oncol, 2002, 32, p. 525-529.

17. Gorelik, E., Landsittel, DP., Marrangoni, AM., et. al. Multiplexed immunobead – based cytokine profilig for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev, 2005, 14., p. 981-987.

18. Gorg, A., Weiss, W., Dunn, MJ. Current two – dimensional electrophoresis technology for proteomics. Proteomics, 2004, 4, p. 3665-3685.

19. Helánová, Š., Vyzula, R., Žaloudík, J., et al. Technologie Ciphergen – nová perspektiva v proteomice nádorových onemocnění. Klin Onkol, 2004, 5, s. 157-161.

20. Hellstrom, I., Raycraft, J., Hayden-Ledbetter, M., Ledbetter, JA. The HE4 protein is a biomarker for ovarian carcinoma. Cancer Res, 2003, 63, p. 3695-3700.

21. Christodoulides, N., Floriano, PN., Miller, CS., et al. Lab on a chip methods for point of care measurements of salivary biomarkers of periodontitis. Ann NY Acad Sci, 2007, 1098, p. 441-428.

22. Immler, D., Greven, S., Reinemer, P. Targeted proteomics in biomarker validation: Detection and quantification of proteins using a multi-dimensional peptide separation strategy. Proteomics, 2006, 6, p. 2947-2958.

23. Jacobs, I., Bast, RC Jr. The CA 125 tumour-associated antigen. A review of the literature. Hum Reprod, 1989, 4 p. 1-12.

24. Jemal, A., Siegel, R., Ward, E., Murray, T. Cancer statistics. CA Cancer J Clin, 2007, 57, p. 43-66.

25. Kacerovský, M. Proteomika a plodová voda. Gynekolog, 2008, 17, s. 118-120.

26. Kachman, MT., Wang, H., Schwartz, DR., et al. A 2-D liquid separations mass mapping method for interlysate comparison of ovarian cancers. Anal Chem, 2002, 74, p. 1779-1791.

27. Kim, JH., Skates, SJ., Uede, T., et al. Osteoponin as a potential diagnostic biomarker for ovarian cancer. JAMA, 2002, 287, p. 1671-1679.

28. Kim, J., Herlyn, D., Wong, KK., et al. Identification of epithelial cell adhesion molecule autoantibody in patient with ovarian cancer. Clin Cancer Res, 2003, 9, p. 4782-4791.

29. Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M. Tissue microarrays for high-throughput molecular profilig of tumor speciments. Nat Med, 1997, 4, p. 844-847.

30. Kozak, K., Su, F., Whitelegge, JP., et al. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics, 2005, 5, p. 4589-4596.

31. Kristensen, GB., Trope, C. Epithelial ovarian carcinoma. Lancet, 1997, 349, p. 113-117.

32. Laemmli, UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970, 225, p. 680-685.

33. Le Page, C., Ouellet, V., Madore, J., et al. From gene profilig to diagnostic markers: IL-18 and FGF -2 complement CA – 125 as serum based markers in epithelial ovarian cancer. Int J Cancer, 2006, 118, p. 1750-1758.

34. Luborsky, JL., Barua, A., Shatavi, SV., Kebede, T. Anti-tumor antibodies in ovarian cancer. Am J Reprod Immunol, 2005, 54, p. 55-62.

35. Luo, LY., Katsaros, D., Scorilas, A., Fracchioli, S. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res, 2003, 63, p. 807-811.

36. Malaynkar, UM. Tumor associated antigens and biomarkers in cancer and immune. Int Rev Immunol, 2007, 26, p. 223-247.

37. McIntosh, MW., Drescher, C., Karlan, B., et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol, 2004, 95, p. 9-15.

38. Mok, SC., Chao, J., Skates, S., Wong, K. Prostasin, a potential serum marker for ovarian cancer. Identification through microarray technology. J Natl Cancer Inst, 2001, 93, p. 1458-1464.

39. Moore, LE., Fung, ET., McGuire, M., et al. Evaluation of apolipoprotein A1 and post translationally modified forms of transthyretin as biomarker for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev, 2006, 15, p. 1641-1646.

40. Mor, G., Visintin, I., Lai, Y., Zhao, H. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA, 2005, 102, p. 7677-7682.

41. Nam, JM., Thaxton, CS., Mirkin, CA. Nanoparticle based bio-bar-codes for the ultrasensitive detection of proteins. Science, 2003, 301, p. 1884-1886.

42. Narasimhan, K., Changqing, Z., Choolani, M. Ovarian cancer proteomic: Many technologie one goal. Proteomics Clin Appl, 2008, 2, p. 195-218.

43. Nesvizhiskii, AI. Protein identification by tandem mass spektrometry and sequence database searching. Methods Mol Biol, 2006, 367, p. 87-120.

44. Oikonomopoulou, K., Scorilas, A., Michael, IP., et al. Kallikreins as markers of disseminated tumors cells in ovarian cancer – a pilot study. Tumour Biol, 2006, 27, p. 104-114.

45. Petricoin, EF., Ardekani, AM., Hitt, BA., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 2002, 359, p. 572-577.

46. Pierce, A., Unwid, RD. Evans, CA., et al. Eight – channel iTRAQ enables comparison of the aktivity of 6 leukaemogenic tyrosine kinases. Mol Cell Proteomics, 2006, 7, p. 927-937.

47. Rifai, N., Gillette, MA., Carr, SA. Protein biomarker discovery and validation. The long and uncertain path to clinical utility. Nat Biotechnol, 2006, 24, p. 971-983.

48. Rosenthal, AN., Jacobs, IJ. The role CA 125 in screening for ovarian cancer. Int J Biol Markers, 1998, 13, p. 216-220.

49. Schorge, JO., Drake, RD., Lee, H., Skates, S. Osteoponin as an adjunct to CA – 125 in detecting recurrent ovarian cancer. Clin Cancer Res, 2004, 10, p. 3474-3478.

50. Simon, I., Zhuo, S., Corral, L., et al. B7-H4 is a novel membrane bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res, 2006, 66, p. 1570-1575.

51. Skates, S., Iliopoulos, O. Molecular markers for early detection of renal carcinoma: Investigative approach. Clin Cancer Res, 2004, 10, p. 6296-6301.

52. Sutphen, R., Xu, Y., Wilbanks, GD., Fiorica, J. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev, 2004, 13, p. 1185-1191.

53. Swanson, SK., Washburn, MP. The continuing evolution of shotgun proteomics. Drug Discov Today. 2005, 15, p. 719-725.

54. Unlu, M., Morgan, ME., Minden, JS. Difference gel electrophoresis: a single gel method for detection changes in protein extracts. Electrophoresis, 1997, 18, p. 835-840.

55. Wang, J., Zhang, X., Ge, X., et al. Proteomic studies of early- stage and advanced ovarian cancer patiens. Gynecol Oncol, 2008, 111, p. 111-119.

56. Woolas, RP., Xu, FJ., Jacobs, IJ, Yu, YH. Elevation of multiple serum markers in patiens with stage I ovarian cancer. J Natl Cancer Inst, 1993, 85, p. 1748-1751.

57. www.fda.gov.

58. Xu, FJ., Ramakrishnan, S., Daly, L., et al. Incerase serum levels of macrophage colony stimulating factor in ovarian cancer. Am J Obstet Gynecol, 1991, 165, p. 1356-1362.

59. Ye, B., Cramer, DW., Skates, SJ., Gygi, SP. Haptoglobin – alpha subunit as potential serum biomarker in ovarian cancer. Identification and characterization using proteomic profilig and mass spektrometry. Clin Cancer Res, 2003, 9, p. 2904-2911.

60. Ye, B., Gagnon, A., Mok, SC. Recent Technical strategies to identify diagnostic biomarkers of ovarian cancer. Expert Rev Proteomics, 2007, 5, p. 121-131.

61. Zhang, Z., Bast, RC Jr., Yu, Z., et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res, 2004, 64., p. 5882-5890.